Simultaneous optimal integration of photovoltaic distributed generation and battery energy storage system in active distribution network using chaotic grey wolf optimization

Goal. The integration of photovoltaic distributed generations in the active distribution network has raised quickly due to their importance in delivering clean energy, hence, participating in solving various problems as climate change and pollution. Adding the battery energy storage systems would be considered as one of the best choices in giving solutions to the mentioned issues due to its characteristics of quick charging and discharging, managing the quality of power, and fulfilling the peak of energy demand. The novelty of the proposed work is the development of new multi-objective functions based on the sum of the three technical parameters of total active power loss, total voltage deviation, and total operation time of the overcurrent protection relay. Purpose. This paper is dedicated for solving the allocation problem of hybrid photovoltaic distributed generation and battery energy storage systems integration in the standard IEEE 33-bus and IEEE 69-bus active distribution networks. Methodology. The optimal integration of the hybrid systems is formulated as minimizing the proposed multi-objective functions by applying a newly developed metaheuristic technique based on various chaotic grey wolf optimization algorithms. The applied optimization algorithms are becoming increasingly popular due to their simplicity, lack of gradient information needed, ability to bypass local optima, and versatility in power system applications. Results. The simulation results of both test systems confirm the robustness and efficiency of the chaotic logistic grey wolf optimization algorithm compared to the rest of the algorithms in terms of convergence to the global optimal solution and in terms of providing the best and minimum multi-objective functions-based power losses, voltage deviation and relay operation time values. Practical significance. Recommendations have been developed for the use of optimal allocation of hybrid systems for practical industrial distribution power systems with the renewable energy sources presence.Мета. Інтеграція фотоелектричної розподіленої генерації в активну розподільчу мережу швидко зросла завдяки її важливості для доставки чистої енергії, отже, участі у вирішенні різних проблем, таких як зміна клімату та забруднення. Додавання акумуляторних систем накопичення енергії може бути розглянуто як один з найкращих варіантів вирішення зазначених питань завдяки своїм характеристикам швидкої зарядки та розрядки, управління якістю енергії та задоволення піку енергетичних потреб. Новизна запропонованої роботи полягає у розробці нових багатоцільових функцій на основі суми трьох технічних параметрів сумарних втрат активної потужності, загальних відхилень напруги та загального часу спрацьовування реле захисту від перевантаження по струму. Мета. Стаття присвячена вирішенню проблеми розподілу гібридних фотоелектричних розподілених систем генерації та інтеграції систем накопичення енергії в стандартні активні розподільчі мережі з 33-шинами IEEE та 69-шинами IEEE. Методологія. Оптимальна інтеграція гібридних систем сформульована як мінімізація запропонованих багатоцільових функцій шляхом застосування нещодавно розробленої метаевристичної методики, заснованої на різних хаотичних алгоритмах оптимізації сірого вовка. Застосовані алгоритми оптимізації стають дедалі популярнішими завдяки своїй простоті, відсутності необхідної інформації щодо градієнту, можливості обходу локальних оптимумів та універсальності в застосуваннях щодо енергосистеми. Результати. Результати моделювання обох тестових систем підтверджують надійність та ефективність хаотичного логістичного алгоритму оптимізації сірого вовка в порівнянні з іншими алгоритмами з точки зору збіжності до глобального оптимального розв‘язання та з точки зору забезпечення найкращих і мінімальних багатоцільових функцій на основі втрат потужності, відхилення напруги та значень часу спрацювання реле. Практичне значення. Розроблено рекомендації щодо використання оптимального розподілу гібридних систем для реальних промислових розподільчих енергосистем із наявністю відновлюваних джерел енергії

Inhibitory Activity of Leaves Extracts of Citrullus colocynthis Schrad. on HT29 Human Colon Cancer Cells

Aims: Citrullus colocynthis is a plant endemic in Asia, Africa and in the Mediterranean basin. It is used in folk medicine against infections, inflammations and cardiovascular and immune-related diseases. There are further evidences of the use of Citrullus colocynthis Schrad in the treatment of cancer in traditional practices. The present study aimed to determine the potential antiproliferative effects of different Citrullus colocynthis leaf extracts on human cancer cells. Methodology: Antiproliferative and antioxidant effects on HT-29 human colon cancer cells were detected by MTS assay and a modified protocol of the alkaline Comet assay. In vitro antioxidant activities of different leaf extracts were evaluated through DPPH, \u3b2-carotene/linoleic acid and reducing power assays. Results: The leaf chloroform extract exhibited the higher cell growth inhibitory activity without induction of DNA damage; it showed to be able to significantly decrease DNA damage induced by H2O2 (100 M). This antioxidant activity seems to be comparable to that of vitamin C (1 mM). Ethyl acetate, acetone and methanol leaf extracts showed to be the most effective in reducing the stable free DPPH radical (IC50 =113 g/ml), in transforming the Fe3+ to Fe2+ (IC50 = 134 \ub5g/ml) and in inducing linoleic acid oxidation with an inhibition of 31.9 %. Conclusion: Our results confirm the antiproliferative potential of Citrullus colocynthis Schrad. on human cancer cells

Conservative route to genome compaction in a miniature annelid

The causes and consequences of genome reduction in animals are unclear because our understanding of this process mostly relies on lineages with often exceptionally high rates of evolution. Here, we decode the compact 73.8-megabase genome of Dimorphilus gyrociliatus, a meiobenthic segmented worm. The D. gyrociliatus genome retains traits classically associated with larger and slower-evolving genomes, such as an ordered, intact Hox cluster, a generally conserved developmental toolkit and traces of ancestral bilaterian linkage. Unlike some other animals with small genomes, the analysis of the D. gyrociliatus epigenome revealed canonical features of genome regulation, excluding the presence of operons and trans-splicing. Instead, the gene-dense D. gyrociliatus genome presents a divergent Myc pathway, a key physiological regulator of growth, proliferation and genome stability in animals. Altogether, our results uncover a conservative route to genome compaction in annelids, reminiscent of that observed in the vertebrate Takifugu rubripes

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402